NDAORALTABLET
Approved
Apr 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
4/8 — Partial
STENDRA (avanafil) by Hetero is (no) in the corpus cavernosum during sexual stimulation. Approved for erectile dysfunction in adult males, erectile dysfunction (). First approved in 2012.
Drug data last refreshed 8h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STENDRA (avanafil) is an oral small-molecule phosphodiesterase-5 (PDE5) inhibitor approved for erectile dysfunction in adult males. It works by inhibiting PDE5 in the corpus cavernosum, enhancing nitric oxide-mediated cGMP accumulation and smooth muscle relaxation to enable penile blood inflow during sexual stimulation. Avanafil demonstrates >100-fold selectivity for PDE5 over PDE6, reducing off-target visual side effects compared to earlier PDE5 inhibitors.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30/100); brand teams likely focused on market maintenance and defensive positioning rather than expansion.
Mechanism of Action
(NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cGMP, producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Avanafil has no direct relaxant effect on isolated human…
Indications (2)
Worked on STENDRA at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.